ArticleLancet regional health. Americas2026
5-Year effectiveness of an oral cholera vaccine in a cholera outbreak in rural Haiti: a case-control study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The World Health Organization recommends use of killed oral cholera vaccines (kOCV) as part of cholera prevention and control, but data on the duration of effectiveness of the most widely available vaccine, Euvichol® is limited. We evaluated the effectiveness of Euvichol® 5 years after a kOCV campaign conducted in Haiti in 2017. Methods: We undertook a frequency-matched case-control study in Mirebalais, Haiti between October 2022 and February 2023. Cases were patients with acute watery diarrhea, had a stool sample positive for Findings: We analyzed 93 cases and 135 controls. 22% of the cases and 51% of the controls self-reported vaccination. Receiving Euvichol in 2017 was associated with a 5-year adjusted VE of 78% (95% CI: 57%-89%, p < 0.0001). Interpretation: Receiving any Euvichol® effectively protected against cholera in Haiti, 5 years after a two-dose vaccination campaign. This has important implications for public health planning, especially in considering of the appropriate timing of boosting schedules and comparative effectiveness analyses. Funding: US National Institute of Allergy and Infectious Diseases of the National Institutes of Health and the Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.